RxDoctor Payments DataLook up a doctor →

Andrea Rupe, NP

Family · Galax, VANPI 1942430335

Payments from drug & device makers

$13,154in general payments, 2019–2025

Across 851 payments — averaging $15.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • Otsuka America Pharmaceutical, Inc.$688
  • Abbott$659
  • plus $7K from 44 others

What the payments were for

  • Food & beverage$13,154100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,154 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$116,129
Medicare patients
176
Services billed
2,669

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide143$162,721
FarxigaDapagliflozin Propanediol224$160,859
OzempicSemaglutide68$89,088
EliquisApixaban114$81,460
MounjaroTirzepatide48$49,287
JardianceEmpagliflozin49$46,943
Tresiba Flextouch U-100Insulin Degludec33$41,477
Tresiba Flextouch U-200Insulin Degludec13$37,992
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$37,236
JanuviaSitagliptin Phosphate39$31,309
CreonLipase/Protease/Amylase13$28,641
RexultiBrexpiprazole18$25,715
ProliaDenosumab14$24,518
KerendiaFinerenone21$21,809
NexletolBempedoic Acid30$21,092

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$1,017$212,009191 claims
AstraZenecaFarxiga, Symbicort$1,538$166,132242 claims
Novo NordiskOzempic$1,324$89,08868 claims
PfizerEliquis, Abrysvo$533$86,891131 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$581$52,599105 claims
Boehringer IngelheimJardiance$111$46,94349 claims
AbbVieCreon, Linzess$1,405$43,00840 claims
MerckJanuvia$33$31,30939 claims
Otsuka America Pharmaceutical, Inc.Rexulti$688$25,71518 claims
AmgenProlia$574$24,51814 claims
BayerKerendia$316$21,80921 claims
Esperion Therapeutics, Inc.Nexletol$157$21,09230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.

Other family in Galax

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →